MANCHESTER, England--(BUSINESS WIRE)--Dmytro Razborov has been appointed Regional Director of Synexus’ Ukraine with responsibility for operations and business development. Dmytro will report to Gabor Kiss who heads up Synexus’ four Dedicated Research Centres in Central and Eastern Europe.
Commenting on the appointment of Dmytro, Gabor Kiss said: “We are delighted to have Dmytro on board. He is joining Synexus at a time when our business in the Central and Eastern European region is continuing to grow and when we are seeing sustained interest from numerous leading trial sponsors.”
Synexus is confident that pharma and CROs will continue to place more studies in the Ukraine and take advantage of the large treatment naïve population there. Dr Christophe Berthoux the company’s Chief Executive is keen to underline this confidence, saying: “In Kiev alone we have a population in excess of 2.5 million. Our site is part of an extremely modern and highly regarded hospital where our team have very positive relationships with the consultants. In addition to this, we are working with patients who are keen to join clinical trials so that they can benefit from higher standards of healthcare than they might otherwise afford. The drop out rates here are considerably lower than in Western Europe and the doctor-patient relationship is generally stronger and with higher levels of respect and trust.”
Before joining Synexus, Dmytro was Head of the Department of Clinical Trials Co-ordination at Kiev Clinical Hospital, and prior to that he worked for the leading CRO in Ukraine, InnoPharm, where he was a director. As part of his extensive training in Good Clinical Practice, Dmytro has also undertaken PPD Clinical Manager Training.
Synexus notes:
Synexus® headquartered in Manchester, England, is the world’s largest multi-national company dedicated to the recruitment and running of clinical trials at its own research centres across the globe on behalf of its pharmaceutical, biotech and CRO clients. Synexus now has 26 Dedicated Research Centres across the UK, Germany, Austria, Poland, Hungary, Ukraine, Bulgaria, India and South Africa staffed by full-time GCP-trained investigators.